This post was adapted from its original source on Fierce Biotech and can be viewed here.
By combining artificial intelligence and an extensive atlas of protein biology, Cyclica is taking new approaches to searching for old drugs that could fight COVID-19—and, now, it’s helped find what could become a first-in-class candidate.
While other drug and vaccine developers hold up the body’s ACE2 receptor as the lock and the coronavirus’s spike protein as the key that opens up the cell for infection, Cyclica has focused on everything on the other side of the door.